Menu
Back to Journals » Biologics: Targets and Therapy » Volume 3
Biologics: Targets and Therapy
ISSN: 1177-5491
- View all (490)
- Volume 17, 2023 (11)
- Volume 16, 2022 (18)
- Volume 15, 2021 (40)
- Volume 14, 2020 (13)
- Volume 13, 2019 (17)
- Volume 12, 2018 (19)
- Volume 11, 2017 (14)
- Volume 10, 2016 (18)
- Volume 9, 2015 (17)
- Volume 8, 2014 (27)
- Volume 7, 2013 (28)
- Volume 6, 2012 (46)
- Volume 5, 2011 (9)
- Volume 4, 2010 (31)
- Volume 3, 2009 (45)
- Volume 2, 2008 (89)
- Volume 1, 2007 (48)
Archive: Volume 3, 2009
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Ara Metjian, Charles S Abrams
Biologics: Targets and Therapy 2009, 3:499-513
Published Date: 4 December 2009
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project
Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al
Biologics: Targets and Therapy 2009, 3:485-498
Published Date: 19 November 2009
Targeted therapy in melanoma
Hussein Tawbi, Neelima Nimmagadda
Biologics: Targets and Therapy 2009, 3:475-484
Published Date: 16 October 2009
Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments
Gesmar RS Segundo, Fabíola A Gomes, Karla P Fernandes, et al
Biologics: Targets and Therapy 2009, 3:469-474
Published Date: 1 October 2009
A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
Regina P El Dib, Gregory M Pastores
Biologics: Targets and Therapy 2009, 3:459-468
Published Date: 28 September 2009
Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
Manil Kukar, Olga Petryna, Petros Efthimiou
Biologics: Targets and Therapy 2009, 3:443-457
Published Date: 28 September 2009
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Jia Li, Muhammad Wasif Saif
Biologics: Targets and Therapy 2009, 3:429-441
Published Date: 7 September 2009
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Bryan A Faller, Barbara Burtness
Biologics: Targets and Therapy 2009, 3:419-428
Published Date: 14 September 2009
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
Deborah Elstein, Ari Zimran
Biologics: Targets and Therapy 2009, 3:407-417
Published Date: 31 August 2009
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
Laith Altaweel, Daniel Sweeney, Xizhong Cui, et al
Biologics: Targets and Therapy 2009, 3:391-406
Published Date: 15 September 2009
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
Francesca Cainelli, Alfredo Vallone
Biologics: Targets and Therapy 2009, 3:385-390
Published Date: 17 August 2009
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Viroj Wiwanitkit
Biologics: Targets and Therapy 2009, 3:377-383
Published Date: 5 August 2009
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
Damiano Paolicelli, Vita Direnzo, Maria Trojano
Biologics: Targets and Therapy 2009, 3:369-376
Published Date: 13 July 2009
First-line treatment of acute lymphoblastic leukemia with pegasparaginase
Riccardo Masetti, Andrea Pession
Biologics: Targets and Therapy 2009, 3:359-368
Published Date: 7 July 2009
Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Claire Booth, H Bobby Gaspar
Biologics: Targets and Therapy 2009, 3:349-358
Published Date: 24 June 2009
Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review
Bernd Th Krause, Ralf Ohlinger, Annette Haase
Biologics: Targets and Therapy 2009, 3:337-347
Published Date: 26 June 2009
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
Junichiro Sageshima, Gaetano Ciancio, Linda Chen, George W Burke III
Biologics: Targets and Therapy 2009, 3:319-336
Published Date: 17 June 2009
Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
Jochen Schmitt, Gottfried Wozel
Biologics: Targets and Therapy 2009, 3:303-318
Published Date: 11 June 2009
HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu Modi
Biologics: Targets and Therapy 2009, 3:289-301
Published Date: 11 June 2009
The old and new therapeutic approaches to the treatment of giardiasis: Where are we?
Haendel GNO Busatti, Joseph FG Santos, Maria A Gomes
Biologics: Targets and Therapy 2009, 3:273-287
Published Date: 5 June 2009
Early stage and long term treatment of multiple sclerosis with interferon-β
Angela Applebee, Hillel Panitch
Biologics: Targets and Therapy 2009, 3:257-271
Published Date: 28 May 2009
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Arvind Kumar, Tryambak D Singh, Santosh K Singh, Satya Prakash
Biologics: Targets and Therapy 2009, 3:245-256
Published Date: 15 May 2009
Potentials and limitations of microorganisms as renal failure biotherapeutics
Poonam Jain, Sapna Shah, Razek Coussa, Satya Prakash
Biologics: Targets and Therapy 2009, 3:233-243
Published Date: 18 May 2009
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
Joseph M Tuscano, Jacob Sands
Biologics: Targets and Therapy 2009, 3:225-232
Published Date: 13 May 2009
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Chad A Reade, Apar Kishor Ganti
Biologics: Targets and Therapy 2009, 3:215-224
Published Date: 11 May 2009
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
Radhakrishnan Ramchandren, Charles A Schiffer
Biologics: Targets and Therapy 2009, 3:205-214
Published Date: 8 May 2009
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
Irina Petrache, Joud Hajjar, Michael Campos
Biologics: Targets and Therapy 2009, 3:193-204
Published Date: 4 May 2009
Infliximab in the treatment of rheumatoid arthritis
A Perdriger
Biologics: Targets and Therapy 2009, 3:183-191
Published Date: 7 May 2009
Long-term pegylated interferon-α and its potential in the treatment of melanoma
Reinhard Dummer, Joanna Mangana
Biologics: Targets and Therapy 2009, 3:169-182
Published Date: 17 April 2009
Ustekinumab in the therapy of chronic plaque psoriasis
Jenna L O’Neill, Robert E Kalb
Biologics: Targets and Therapy 2009, 3:159-168
Published Date: 25 March 2009
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
Lawrence Rice
Biologics: Targets and Therapy 2009, 3:151-157
Published Date: 19 March 2009
Management of chronic hepatitis C treatment failures: role of consensus interferon
Stevan A Gonzalez, Emmet B Keeffe
Biologics: Targets and Therapy 2009, 3:141-150
Published Date: 18 March 2009
Challenges in the management of juvenile idiopathic arthritis with etanercept
Clare E Pain, Liza J McCann
Biologics: Targets and Therapy 2009, 3:127-139
Published Date: 16 March 2009
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
Steven Pipe
Biologics: Targets and Therapy 2009, 3:117-125
Published Date: 16 February 2009
Palifermin for management of treatment-induced oral mucositis in cancer patients
Andrei Barasch, Joel Epstein, Ken Tilashalski
Biologics: Targets and Therapy 2009, 3:111-116
Published Date: 16 February 2009
Front line treatment of elderly multiple myeloma in the era of novel agents
Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al
Biologics: Targets and Therapy 2009, 3:99-109
Published Date: 30 October 2008
Biologic targeting in the treatment of inflammatory bowel diseases
Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro
Biologics: Targets and Therapy 2009, 3:77-97
Published Date: 9 February 2009
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Caitriona McLean, Catherine M Greene, Noel G McElvaney
Biologics: Targets and Therapy 2009, 3:63-75
Published Date: 21 January 2009
Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
Eric Cheung, Howard A Liebman
Biologics: Targets and Therapy 2009, 3:57-62
Published Date: 8 January 2009
Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan
Biologics: Targets and Therapy 2009, 3:51-56
Published Date: 12 January 2009
Maintenance treatment with infliximab for the management of Crohn’s disease in adults
Renato Caviglia, Ivo Boškoski, Michele Cicala
Biologics: Targets and Therapy 2009, 3:39-49
Published Date: 5 January 2009
Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad
Biologics: Targets and Therapy 2009, 3:27-37
Published Date: 17 December 2008
Current available therapies and future directions in the treatment of malignant gliomas
Annick Desjardins, David A Reardon, James J Vredenburgh
Biologics: Targets and Therapy 2009, 3:15-25
Published Date: 17 December 2008
Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano Lombardi
Biologics: Targets and Therapy 2009, 3:9-13
Published Date: 2 December 2008
Botulinum toxin type A in the treatment of patients with cervical dystonia
Allison Brashear
Biologics: Targets and Therapy 2009, 3:1-7
Published Date: 1 December 2008